Format

Send to

Choose Destination
See comment in PubMed Commons below
J Med Chem. 2009 Nov 26;52(22):6958-61. doi: 10.1021/jm901181h.

Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine.

Author information

1
Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana 46285, USA. dbender@lilly.com

Abstract

The design, synthesis, and biological characterization of an orally active prodrug (3) of gemcitabine are described. Additionally, the identification of a novel co-crystal solid form of the compound is presented. Valproate amide 3 is orally bioavailable and releases gemcitabine into the systemic circulation after passing through the intestinal mucosa. The compound has entered clinical trials and is being evaluated as a potential new anticancer agent.

PMID:
19860433
DOI:
10.1021/jm901181h
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Chemical Society
    Loading ...
    Support Center